CD44 and breast carcinoma: A study comparing the behavior of SERS NPs conjugated with HER2 and CD44 antibodies with the corresponding fluorescent-labeled antibodies, in the targeting of their receptors in breast cancer cells, Raman images demonstrated cell labeling with a high specificity that correlated well with fluorescent labels (Figure 5).